Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
Cryoport Inc (NASDAQ: CYRX) provides mission-critical temperature-controlled logistics solutions for the life sciences industry, specializing in cell/gene therapies and biologics transport. This page serves as the definitive source for verified corporate announcements, financial updates, and operational developments.
Investors and industry professionals will find timely updates on earnings reports, strategic partnerships, technology innovations, and regulatory milestones. All content is curated to support informed decision-making while adhering to financial disclosure standards.
The repository includes press releases covering logistics network expansions, new cryogenic system deployments, and clinical trial support agreements. Each update reflects Cryoport's role in enabling safe biological material transport across 50+ global locations.
Bookmark this page for direct access to primary source materials about Cryoport's temperature-controlled supply chain solutions, maintained with strict neutrality and compliance with financial reporting guidelines.
MVE Biological Solutions (NASDAQ: CYRX) unveiled integrated real-time condition monitoring for its MVE SC 4/2 V and 4/3 V cryogenic dewars on Oct 7, 2025. The systems embed SmartTag (LTE, up to 120 days battery) or CryoBeacon (BLE 5.0, logs to –200°C plus ambient humidity) into dewar lids and stream data to MVECloud, an FDA 21 CFR Part 11 and GAMP 5 compliant web/mobile platform offering visibility, real-time alerts, QR-based data retrieval, and reporting.
The launch positions MVE to offer connected assets for shipments and stationary storage and to pursue services and potential subscription-based revenue as part of Cryoport's broader monitoring strategy.
MVE Biological Solutions (NASDAQ: CYRX) unveiled integrated real-time condition monitoring for its MVE SC 4/2 V and 4/3 V cryogenic dewars on Oct 7, 2025. The systems embed SmartTag (LTE, up to 120 days battery) or CryoBeacon (BLE 5.0, logs to –200°C plus ambient humidity) into dewar lids and stream data to MVECloud, an FDA 21 CFR Part 11 and GAMP 5 compliant web/mobile platform offering visibility, real-time alerts, QR-based data retrieval, and reporting.
The launch positions MVE to offer connected assets for shipments and stationary storage and to pursue services and potential subscription-based revenue as part of Cryoport's broader monitoring strategy.
Cryoport (NASDAQ: CYRX) has announced the opening of a new 55,000-square-foot Global Supply Chain Center (GSCC) in Louvres, France, near Paris Charles de Gaulle Airport. The facility represents the company's third global supply chain center campus, strengthening its temperature-controlled supply chain solutions network.
The Paris GSCC will provide 24-hour worldwide dispatch capabilities and immediate logistics support for biopharma, including cell and gene therapies, biologics, animal health, and reproductive medicine. Future phases will incorporate BioServices, biostorage, QP drug management, and Importer of Record services. The facility's development was partially funded by a grant from the Île-de-France region, with an official grand opening scheduled for November 20, 2025.
Cryoport (NASDAQ: CYRX) has announced the opening of a new 55,000-square-foot Global Supply Chain Center (GSCC) in Louvres, France, near Paris Charles de Gaulle Airport. The facility represents the company's third global supply chain center campus, strengthening its temperature-controlled supply chain solutions network.
The Paris GSCC will provide 24-hour worldwide dispatch capabilities and immediate logistics support for biopharma, including cell and gene therapies, biologics, animal health, and reproductive medicine. Future phases will incorporate BioServices, biostorage, QP drug management, and Importer of Record services. The facility's development was partially funded by a grant from the Île-de-France region, with an official grand opening scheduled for November 20, 2025.
Cryoport (NASDAQ: CYRX) reported strong Q2 2025 financial results with total revenue increasing 14% year-over-year to $45.5 million. The company's Commercial Cell & Gene Therapy revenue grew 33% to $8.7 million, while Life Sciences Services revenue rose 21%, including a 28% increase in BioStorage/BioServices revenue.
Key highlights include the completion of a strategic partnership with DHL Group and the divestiture of CRYOPDP, resulting in a significant capital infusion. The company supports 728 global clinical trials, including 82 in Phase 3. Cryoport maintained its full-year 2025 revenue guidance of $165-172 million and reported $426 million in cash and equivalents as of June 30, 2025.
Cryoport (NASDAQ:CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, has scheduled its Q2 2025 earnings release for August 5, 2025 after U.S. markets close.
The company will release a document titled "Cryoport Second Quarter 2025 in Review" at 4:05 p.m. ET, followed by a Q&A conference call at 5:00 p.m. ET. Management will address questions from the investment community regarding the reported results, accompanied by a slide deck presentation.
The earnings call can be accessed via phone (U.S.: 1-800-717-1738, International: 1-646-307-1865) or webcast through the company's investor relations website. A replay will be available until August 12, 2025.
Cryoport (NASDAQ:CYRX) has announced the launch of its next-generation vapor shippers, the SC 4/2V and SC 4/3V, through its MVE Biological Solutions division. The new models feature significant improvements in hold times, with the SC 4/2V extending from 13 to 19 days and the SC 4/3V from 21 to 26 days.
The enhanced vapor shippers incorporate several innovative features, including the patented BEND DON'T BREAK™ technology for impact absorption, an integrated lid locking tab, and patent-pending Vapor Shield Technology to prevent vacuum loss. These improvements are designed to provide better protection for sensitive biological materials during transportation, including cells, tissues, vaccines, and reproductive health materials.
Cryoport (NASDAQ: CYRX) reported Q1 2025 revenue of $41.0 million from continuing operations, up 10% year-over-year. The company's commercial Cell & Gene therapy revenue grew 33%, while Life Sciences Services revenue increased 17%. As of March 31, 2025, Cryoport supported 711 global clinical trials, including 79 in Phase 3. The company announced a strategic partnership with DHL, including the planned divestiture of CRYOPDP expected to close in Q2/Q3 2025.
Financial highlights include a gross margin of 45.4%, operating costs reduction of 13.7%, and a net loss of $12.0 million ($0.28 per share). The company maintains $244.0 million in cash and investments. For fiscal 2025, Cryoport reiterates revenue guidance of $165.0-172.0 million, representing 5-10% growth.
Cryoport (CYRX), a global life sciences supply chain solutions provider, has scheduled its first quarter 2025 financial results announcement for May 7, 2025 after U.S. markets close. The company will release its earnings report alongside a comprehensive document titled 'Cryoport First Quarter 2025 in Review' at 4:05 p.m. ET, providing detailed financial and operational performance updates.
Management will host a Q&A conference call at 5:00 p.m. ET the same day, accompanied by a slide deck presentation. The call will be accessible via U.S. dial-in (1-800-717-1738) and International dial-in (1-646-307-1865) using Conference ID: 1180684. A webcast replay will be available until May 14, 2025.
FAQ
What is the current stock price of Cryoport (CYRX)?
What is the market cap of Cryoport (CYRX)?
